Cargando…
PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer
Over the last decade, the use of targeted therapies has immensely increased in the treatment of cancer. However, treatment for endometrial carcinomas (ECs) has lagged behind, although potential molecular markers have been identified. This is particularly problematic for the type II ECs, since these...
Autores principales: | Remmerie, Michiel, Janssens, Veerle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558005/ https://www.ncbi.nlm.nih.gov/pubmed/31214504 http://dx.doi.org/10.3389/fonc.2019.00462 |
Ejemplares similares
-
Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late
por: Remmerie, Michiel, et al.
Publicado: (2018) -
Autophagy Machinery as a Promising Therapeutic Target in Endometrial Cancer
por: Nuñez-Olvera, Stephanie I., et al.
Publicado: (2019) -
CEP55 as a promising biomarker and therapeutic target on gallbladder cancer
por: Huang, Maotuan, et al.
Publicado: (2023) -
The Basic Biology of PP2A in Hematologic Cells and Malignancies
por: Haesen, Dorien, et al.
Publicado: (2014) -
GFAPδ: A Promising Biomarker and Therapeutic Target in Glioblastoma
por: Radu, Roxana, et al.
Publicado: (2022)